Brussels, Belgium, May 22, 2007 at 7:00 AM (CET) - UCB announced today that new data presented at Digestive Disease Week 2007 (DDW) demonstrated long-term response and remission in Crohn’s disease patients treated with CIMZIA™ (certolizumab pegol), the only Fc-free PEGylated, Fab’ fragment anti-TNF.
